

ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside

Newly granted continuation patent provides additional intellectual property protection for ChromaDex's Niagen® (patented nicotinamide riboside) ingredient

LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. ChromaDex currently holds a robust patent portfolio of over 40 granted or licensed patents relating to Niagen® (patented NR) and other precursors to NAD, a molecule at the forefront of the healthy aging and cellular health categories. Niagen® is the sole active ingredient in ChromaDex's flagship product, Tru Niagen®.

"We believe Niagen, or NR, is the most important supplement ingredient to have emerged in many years," said Rob Fried, CEO of ChromaDex. "The science shows that it is important to anyone concerned about physiological aging. This patent further strengthens the ChromaDex position as the legal and safe way to obtain NR."

U.S. Patent No. 11,242,364, which expires Nov. 10, 2037, significantly reinforces ChromaDex's intellectual property position and adds additional protection of the manufacturing process of nicotinamide riboside (NR) and nicotinamide riboside triacetate (NRT) salts including malate and tartrate salts. This patent allows ChromaDex to protect the process of creating NR and its various salt forms, which can be leveraged via future innovations. The patent continuation will also provide protection for new salt forms ChromaDex may develop in the future.

U.S. Patent No. 11,242,364 is titled "*Efficient and Scalable Syntheses of Nicotinoyl Ribosides and Reduced Nicotinoyl Ribosides, Modified Derivatives Thereof, Phosphorylated Analogs Thereof, Adenylyl Dinucleotide Conjugates Thereof, and Novel Crystalline Forms Thereof.*"

For additional information about ChromaDex, please visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD⁺), levels of which decline with age. ChromaDex is the innovator behind NAD⁺ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD⁺ precursors are protected by ChromaDex's patent portfolio. ChromaDex maintains a website at www.chromadex.com to

which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements related to ChromaDex's intellectual property position and protection provided for new salt forms ChromaDex may develop in the future. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20220209005333/en/>

ChromaDex Media Contact:

Alex Worsham, Vice President of Global Marketing & Communications

310-388-6706 ext. 689

alexw@chromadex.com

ChromaDex Investor Relations Contact:

Brianna Gerber, Vice President of Finance and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com